Elsevier

Placenta

Volume 43, July 2016, Pages 13-16
Placenta

Technical note
Don't trust an(t)ybody - Pitfalls during investigation of candidate proteins for methylmercury transport at the placental interface

https://doi.org/10.1016/j.placenta.2016.04.011Get rights and content

Highlights

  • Specificity of commercial antibodies against LAT1, LAT2, 4F2hc, MRP2 was validated.

  • We found an anti-LAT1 antibody to actually react with LAT2 instead of LAT1.

  • Two anti-LAT2 antibodies detected mainly albumin in placental lysates.

  • A specific antibody hardly detected MRP2 in human placentas, contradicting published data.

  • Our findings underpin the need for rigorous validation of commercial antibodies.

Abstract

While investigating placental mercury transport, we validated specificity of commercial antibodies against four candidate transporters (Large neutral amino acids transporter (LAT)1, LAT2, 4F2 cell-surface antigen heavy chain (4F2hc), and multidrug resistance-associated protein (MRP)2) by immunoblotting and small interfering RNA (siRNA)-mediated protein knockdown. An anti-4F2hc- and one anti-LAT1-antibody were specific. Another anti-LAT1-antibody reacted with LAT2. Two anti-LAT2-antibodies detected mainly albumin in placental lysates. A specific anti-MRP2-antibody hardly detected MRP2 in human placentas, contradicting published data. We recommend testing any unknown antibody by western blotting for 1/specificity for the protein of interest using e.g. siRNA knockdown and 2/cross-reactivity with albumin.

Introduction

The toxic organic mercury compound methylmercury crosses the placenta barrier most likely through active transport [1]. Our knowledge on the involved transporters is poor [2]. Mercury strongly adheres to sulfhydryl groups. Methylmercury-cysteine, a molecular mimicry of methionine [3], is transported into cells by L-type amino acid transporter (LAT) light chains LAT1/SLC7A5 and LAT2/SLC7A8 [4] dimerized to the 4F2 surface antigen heavy chain (4F2hc/CD98/SLC3A2). Exit from cells is assumed to occur as a complex with glutathione (GSH) recognized by GSH-carriers such as multidrug resistance-associated protein 2 (MRP2/ABCC2) [5].

In preparation to functional studies on placental mercury toxicokinetics, we aimed to verify specificity of commercial primary antibodies against LAT1, LAT2, 4F2hc, and MRP2 combining the methods of immunoblotting [6] with target-specific small interfering RNA (siRNA)-mediated knockdown [7]. Current literature suggests that antibody specificity is valid only in 50% of cases [8]. Many researchers worldwide, who invested incredible amounts of money and time into validation, realized this [9], [10], [11]. Despite our awareness that antibodies do not necessarily recognize (only) their specified target, we were quite surprised by the results obtained during validation and want to share the most striking observations with the research community.

Section snippets

Materials and methods

We selected one antibody against 4F2hc, two antibodies against LAT1 and LAT2, respectively, and one further against MRP2 according to two criteria, i.e., recommendation for immunoblotting and provision of immunoblot(s) indicating specificity for a protein of the appropriate size.

Healthy term placentas were obtained after elective cesarean sections. Prior to, all patients gave written informed consent and the study was approved by the ethics committee of the Medical University Vienna (EC-number

System L

The Aviva 4F2hc antibody detected a single placental protein of around 80–90 kDa (Fig. 1A), which is in agreement with previous studies [14]. In BeWo and HeLa cells we detected two bands (Fig. 1A) likely representing two differently glycosylated proteins [15], [16]. Both LAT1 antibodies (Abcam, Fig. 1B; Epitomics, Fig. 1C) detected an appropriate major protein at 40–50 kDa. The LAT2 antibodies (Santa Cruz, Fig. 1D; Abcam, Fig. 1E) showed strong cross-reactivity with albumin in placental lysates

Acknowledgements

The study was supported by LifeScience2010 (Project LS10026), NFB (Niederösterreichische Forschungs- und Bildungsgesellschaft). We thank Prof. John Robinson for providing the highly enriched apical plasma membrane fractions of placental trophoblasts.

References (25)

  • A.H. Stern et al.

    An assessment of the cord blood:maternal blood methylmercury ratio: implications for risk assessment

    Environ. health Perspect.

    (2003)
  • C. Gundacker et al.

    The role of the placenta in fetal exposure to heavy metals

    Wien. Med. Wochenschr. (1946)

    (2012)
  • R.E. Hoffmeyer et al.

    Molecular mimicry in mercury toxicology

    Chem. Res. Toxicol.

    (2006)
  • T.A. Simmons-Willis et al.

    Transport of a neurotoxicant by molecular mimicry: the methylmercury-L-cysteine complex is a substrate for human L-type large neutral amino acid transporter (LAT) 1 and LAT2

    Biochem. J.

    (2002)
  • C.C. Bridges et al.

    Placental and fetal disposition of mercuric ions in rats exposed to methylmercury: role of Mrp2

    Reprod. Toxicol. (Elmsford, NY)

    (2012)
  • B.T. Kurien et al.

    An overview of Western blotting for determining antibody specificities for immunohistochemistry

    Methods Mol. Biol. Clift. NJ)

    (2011)
  • M. Rosner et al.

    Efficient siRNA-mediated prolonged gene silencing in human amniotic fluid stem cells

    Nat. Protoc.

    (2010)
  • L. Berglund et al.

    A genecentric human protein atlas for expression profiles based on antibodies. molecular & cellular proteomics

    MCP

    (2008)
  • A. Bradbury et al.

    Reproducibility: Standardize antibodies used in research

    Nature

    (2015)
  • J. Voskuil

    Commercial antibodies and their validation

    F1000 Res.

    (2014)
  • Z.A. Kemmerer et al.

    Comparison of human Nrf2 antibodies: A tale of two proteins

    Toxicol. Lett.

    (2015)
  • J.M. Robinson et al.

    Isolation of highly enriched apical plasma membranes of the placental syncytiotrophoblast

    Anal. Biochem.

    (2009)
  • Cited by (0)

    1

    Faculty of Medicine, Mahasarakham University, Thailand.

    View full text